Drug intelligence / Profile preview

Globo-H-GM2-sTn-TF-Tn-KLH conjugate + QS-21

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

A cancer vaccine formulation combining multiple tumor-associated carbohydrate antigens (Globo-H, GM2, sTn, TF, and Tn) conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein, administered with QS-21 as an adjuvant. QS-21 is a saponin-based immunomodulatory molecule derived from the Quillaja saponaria tree bark that enhances both humoral and cell-mediated immunity. This combination is designed to stimulate the immune system to recognize and attack cancer cells expressing these carbohydrate antigens.

Beyond the preview

Go deeper on Globo-H-GM2-sTn-TF-Tn-KLH conjugate + QS-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Globo-H-GM2-sTn-TF-Tn-KLH conjugate + QS-21.

Explore the full profile